Key facts
- It has raised $10.0M; the latest was Early Stage VC ($10.0M) in Feb 2025.
- Notable investors include Qiming Venture Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Vivatides Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vivatides Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vivatides Therapeutics
Developer of ribonucleic acid (RNA) therapeutics intended to benefit patients' lives. The company's research focuses on antibody conjugates that allow for more targeted delivery of therapeutic payloads, enabling physicians to prescribe more effective treatments to patients.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2025
- Employees
- 2
- Ownership
- Privately Held (backing)
Vivatides Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vivatides Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vivatides Therapeutics in its N-PORT filings yet. We sweep new filings monthly.